VRNA שולי הרווח הגולמי Verona Pharma Corp

How is the profitability of Verona Pharma plc (VRNA) from Ohtuvayre sales generated? The gross margin percentage reflects efficiency dynamics, with the current metric level standing at 94.60. The business relies on a combination of unique molecules and proprietary nebulizers for precise delivery. Following FDA approval, the drug began commercial growth, offering COPD patients a fundamentally new way to improve breathing.
פילוחים אנליטיים ודוחות נתונים של חברת Verona Pharma Corp (VRNA)

Professional selection of blue-chip assets requires a rigorous analysis of operating expense efficiency. Gross margin measures the profit share after deducting direct production costs, determining a business's ability to generate cash flow. For Verona Pharma plc (VRNA), reliance on outsourced manufacturing directly impacts this metric, which currently stands at 94.60. The trend of gross income as a percentage of revenue allows for an assessment of the company's resilience to market competition.